Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission - PubMed (original) (raw)
Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission
Florian Hladik et al. J Virol. 2005 Sep.
Abstract
Exposed seronegative individuals (ES) with persistent high-risk sexual behavior may be less susceptible to human immunodeficiency virus type 1 (HIV-1) infection because they carry the chemokine receptor (CR) gene alleles CCR5 open reading frame (ORF) Delta32, CCR5 promoter -2459G, or CCR2 ORF 64I (CCR2-64I), all of which have been found to diminish HIV-1 infectivity and/or disease progression. To investigate this, we determined the haplotypes for these three genetic loci in 93 ES and 247 low-risk control individuals. To test if protective haplotypes exert their effect by modulating CR expression, we measured the protein expression of CCR5 and CXCR4 on circulating CD4+ T cells and CD14+ monocytes in 71 ES and 92 controls. To avoid investigator bias, the analysis was performed without knowledge of each subject's risk and genotype. The CCR5 -2459G allele was significantly enriched in ES Caucasian men, who constituted the majority (84%) of the ES cohort, compared to the control Caucasian men (P = 0.02). This increase was mostly attributable to a higher frequency of the -2459 A/G versus the -2459 A/A genotype in individuals heterozygous for the delta32 allele (P = 0.012). No protective influence of the CCR2-64I allele was observed. The haplotypes CCR5 ORF delta32/CCR5 -2459A (in complete linkage disequilibrium) and CCR5 ORF wt/CCR5 -2459G had a cumulative negative effect on the expression of CCR5, since we measured significantly reduced CCR5 densities on both T-helper cells and monocytes only when both haplotypes were present. Densities of CCR5 on lymphocytes and monocytes were correlated (r = 0.59; P < 0.0001), indicating concordance of CCR5 expression patterns across different cell types. We conclude that the CCR5 ORF delta32/wt-CCR5 -2459 A/G genotype combination offers an advantage in resisting sexual HIV-1 transmission and that this effect is mediated by a relative paucity of CCR5 on potential target cells of HIV-1.
Figures
FIG. 1.
Association between CCR5 ORF plus −2459 genotype combinations and CCR5 expression. Stored peripheral blood CD4+ T cells and CD14+ monocytes from 163 individuals were blinded and analyzed by FACS for the mean number of CCR5 surface receptors per CCR5+ cell and the percentage of CCR5-expressing cells. CCR5 genotypes were determined by restriction fragment length polymorphism analysis. Stratification of CCR5 densities and percentages by CCR5 ORF plus −2459 genotype combinations was performed after completion of all FACS analyses. Horizontal bars represent population medians. P values were determined by Mann-Whitney test. wt, wild type.
FIG. 2.
Correlation between T-helper cell and monocyte surface CCR5 densities. Peripheral blood CD4+ T cells and CD14+ monocytes from 163 individuals were analyzed by FACS for the mean number of CCR5 surface receptors per CCR5+ cell. Line fit was done by linear regression. r, Spearman correlation coefficient.
FIG. 3.
HIV-1 infectivity of CD4+ lymphoblasts. CD4-selected, PHA-stimulated lymphoblasts from 102 individuals were infected with HIV-1JR-CSF at MOI of 0.006 (not shown) and 0.003 (shown). p24 concentrations in culture supernatants were determined 7 days after infection. Stratification of p24 values by CCR5 genotype combinations was performed after completion of all infection assays. Numbers next to symbols are the mean number of CCR5 surface receptors per cell measured on peripheral blood CCR5+ CD4+ T cells from the same individuals but obtained at different clinic visits from those used to obtain the cells used for the infectivity assays. nd, not done.
Similar articles
- Distribution of CCR5-Delta32, CCR5 promoter 59029 A/G, CCR2-64I and SDF1-3'A genetic polymorphisms in HIV-1 infected and uninfected patients in the west region of Cameroon.
Nkenfou CN, Mekue LC, Nana CT, Kuiate JR. Nkenfou CN, et al. BMC Res Notes. 2013 Jul 23;6:288. doi: 10.1186/1756-0500-6-288. BMC Res Notes. 2013. PMID: 23880174 Free PMC article. - Adverse effect of the CCR5 promoter -2459A allele on HIV-1 disease progression.
Knudsen TB, Kristiansen TB, Katzenstein TL, Eugen-Olsen J; Copenhagen AIDS Study Group. Knudsen TB, et al. J Med Virol. 2001 Nov;65(3):441-4. J Med Virol. 2001. PMID: 11596075 - [Effects of CCR5-delta32, CCR2-64I and SDF-1-3'A polymorphic alleles on human immunodeficiency virus 1 (HIV-1) infection in the Polish population].
Wasik TJ, Smoleń J, Kruszyński P, Bratosiewicz-Wasik J, Beniowski M. Wasik TJ, et al. Wiad Lek. 2005;58(9-10):500-7. Wiad Lek. 2005. PMID: 16529059 Polish. - HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.
Sheppard HW, Celum C, Michael NL, O'Brien S, Dean M, Carrington M, Dondero D, Buchbinder SP. Sheppard HW, et al. J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):307-13. doi: 10.1097/00126334-200203010-00013. J Acquir Immune Defic Syndr. 2002. PMID: 11873082 Review. - HIV-1 Infection in Persons Homozygous for CCR5-Δ32 Allele: The Next Case and the Review.
Smoleń-Dzirba J, Rosińska M, Janiec J, Beniowski M, Cycoń M, Bratosiewicz-Wąsik J, Wąsik TJ. Smoleń-Dzirba J, et al. AIDS Rev. 2017 Dec;19(4):219-230. AIDS Rev. 2017. PMID: 28534889 Review.
Cited by
- Reduced CCR5 expression among Uganda HIV controllers.
Nyiro B, Amanya SB, Bayiyana A, Wasswa F, Nabulime E, Kayongo A, Nankya I, Mboowa G, Kateete DP, Sande OJ. Nyiro B, et al. Retrovirology. 2023 May 25;20(1):8. doi: 10.1186/s12977-023-00626-7. Retrovirology. 2023. PMID: 37231494 Free PMC article. - Resistance to Human Immunodeficiency Virus 1 Infection Conferred by a Compound CCR5Δ32 and CCR5 C20S Heterozygote.
Alkhatib B, Jabari M, Bilasy S, Abdul-Rahman H, Sandhu K, Lai S, Alkhatib G. Alkhatib B, et al. J Infect Dis. 2023 Jul 14;228(2):116-121. doi: 10.1093/infdis/jiad062. J Infect Dis. 2023. PMID: 36912158 Free PMC article. - CCR5∆32 and SDF1 3'A: Gene Variants, Expression and Influence on Biological Markers for the Clinical Progression to AIDS among HIV-1 Virus Controllers in a Mixed Population of the Amazon Region of Brazil.
Lima ÉRG, Queiroz MAF, Lima SS, Machado LFA, Cayres-Vallinoto IMV, Vallinoto ACR, Figueiredo FAPL, Guerreiro JF, Guimarães Ishak MO, Ishak R. Lima ÉRG, et al. Int J Mol Sci. 2023 Mar 4;24(5):4958. doi: 10.3390/ijms24054958. Int J Mol Sci. 2023. PMID: 36902388 Free PMC article. - Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.
Mohamed H, Gurrola T, Berman R, Collins M, Sariyer IK, Nonnemacher MR, Wigdahl B. Mohamed H, et al. Front Immunol. 2022 Jan 20;12:816515. doi: 10.3389/fimmu.2021.816515. eCollection 2021. Front Immunol. 2022. PMID: 35126374 Free PMC article. Review. - A Polymorphism in C-C Chemokine Receptor 5 (CCR5) Associates with Löfgren's Syndrome and Alters Receptor Expression as well as Functional Response.
Karakaya B, van Moorsel CHM, Veltkamp M, Roodenburg-Benschop C, Kazemier KM, van der Helm-van Mil AHM, Huizinga TWJ, Grutters JC, Rijkers GT. Karakaya B, et al. Cells. 2021 Aug 3;10(8):1967. doi: 10.3390/cells10081967. Cells. 2021. PMID: 34440736 Free PMC article.
References
- Benkirane, M., D. Y. Jin, R. F. Chun, R. A. Koup, and K. T. Jeang. 1997. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J. Biol. Chem. 272:30603-30606. - PubMed
- Clegg, A. O., L. J. Ashton, R. A. Biti, P. Badhwar, P. Williamson, J. M. Kaldor, G. J. Stewart et al. 2000. CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. AIDS 14:103-108. - PubMed
- Cohen, O. J., M. Vaccarezza, G. K. Lam, B. F. Baird, K. Wildt, P. M. Murphy, P. A. Zimmerman, T. B. Nutman, C. H. Fox, S. Hoover, J. Adelsberger, M. Baseler, J. Arthos, R. T. Davey, Jr., R. L. Dewar, J. Metcalf, D. J. Schwartzentruber, J. M. Orenstein, S. Buchbinder, A. J. Saah, R. Detels, J. Phair, C. Rinaldo, J. B. Margolick, A. S. Fauci et al. 1997. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors. J. Clin. Investig. 100:1581-1589. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI045402/AI/NIAID NIH HHS/United States
- AI 35605/AI/NIAID NIH HHS/United States
- T32 GM008169/GM/NIGMS NIH HHS/United States
- K08 AI051980/AI/NIAID NIH HHS/United States
- AI 49109/AI/NIAID NIH HHS/United States
- AI 56994/AI/NIAID NIH HHS/United States
- R21 AI056994/AI/NIAID NIH HHS/United States
- R01 AI049109/AI/NIAID NIH HHS/United States
- AI 51980/AI/NIAID NIH HHS/United States
- R37 AI035605/AI/NIAID NIH HHS/United States
- P30 AI027757/AI/NIAID NIH HHS/United States
- AI 27757/AI/NIAID NIH HHS/United States
- AI 45402/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials